Paul Dent

Dr. Paul Dent

Department of Biochemistry, Virginia Commonwealth University, Richmond, VA 23298, USA

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 October 2012 in Expert Opinion on Therapeutic Targets
Verified
Journal Article
Closed access
STShibu Thomas
Shibu Thomas
BQBridget A Quinn
Bridget A Quinn
SDSwadesh K Das
Swadesh K Das
RDRupesh Dash
Rupesh Dash
LELuni Emdad
Luni Emdad
PFPaul B Fisher
Paul B Fisher
Introduction: Programmed cell death is well-orchestrated process regulated by multiple pro-apoptotic and anti-apoptotic genes, particularly those of the Bcl-2 gene family. These genes are well docu...

27 October 2008 in Cancer Biology & Therapy
Verified
Journal Article
Closed access
MPMargaret A. Park
Margaret A. Park
GZGuo Zhang
Guo Zhang
AMAditi Pandya Martin
Aditi Pandya Martin
HHHossein Hamed
Hossein Hamed
CMClint Mitchell
Clint Mitchell
Paul DentPaul Dent
Paul Dent
We recently noted that low doses of sorafenib and vorinostat interact in a synergistic fashion to kill carcinoma cells by activating CD95, and this drug combination is entering phase I trials. The ...

17 May 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
LBLaurence Booth
Laurence Booth
JRJane L. Roberts
Jane L. Roberts
APAndrew Poklepovic
Andrew Poklepovic
JKJohn Kirkwood
John Kirkwood
Paul DentPaul Dent
Paul Dent
HDAC inhibitors enhance the immunotherapy response of melanoma cells HDAC inhibitors enhance the immunotherapy response of melanoma cells

1 September 2008 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
GZGuo Zhang
Guo Zhang
MPMargaret A. Park
Margaret A. Park
CMClint Mitchell
Clint Mitchell
HHHossein Hamed
Hossein Hamed
MRMohamed Rahmani
Mohamed Rahmani
Paul DentPaul Dent
Paul Dent
Purpose and Design: Mechanism(s) by which the multikinase inhibitor sorafenib and the histone deacetylase inhibitor vorinostat interact to kill hepatic, renal, and pancreatic adenocarcinoma cells has been defined. Results: Low doses of sorafenib and vorinostat interacted in vitro in a synergistic fashion to kill hepatic, renal, and pancreatic adenocarcinoma cells in multiple short-term viability (24-96 h) and in long-term colony formation assays. Cell killing was suppressed by inhibition of cathepsin proteases and caspase-8 and, to a lesser extent, by inhibition of caspase-9. Twenty-four hours after exposure, the activities of extracellular signal-regulated kinase 1/2, AKT, and nuclear factor-κB were only modestly modulated by sorafenib and vorinostat treatment. However, 24 h after exposure, sorafenib- and vorinostat-treated cells exhibited markedly diminished expression of c-FLIP-s, full-length BID, BCL-2, BCL-XL, MCL-1, XIAP, increased expression of BIM, and increased activation of BAX, BAK, and BAD. Expression of eIF2α S51A blocked sorafenib- and vorinostat-induced suppression of c-FLIP-s levels and overexpression of c-FLIP-s abolished lethality. Sorafenib and vorinostat treatment increased surface levels of CD95 and CD95 association with caspase-8. Knockdown of CD95 or FADD expression significantly reduced sorafenib/vorinostat-mediated lethality. Conclusions: These data show that combined exposure of epithelial tumor cell types to sorafenib and vorinostat diminishes expression of multiple antiapoptotic proteins and promotes activation of the CD95 extrinsic apoptotic and the lysosomal protease pathways, and that suppression of c-FLIP-s expression represents a critical event in transduction of the proapoptotic signals from CD95 to promote mitochondrial dysfunction and death.

24 December 2014 in Journal of Cellular Physiology
Verified
Journal Article
Open access
PDF file
LBLaurence Booth
Laurence Booth
JRJane L. Roberts
Jane L. Roberts
DCDevin R. Cash
Devin R. Cash
STSeyedmehrad Tavallai
Seyedmehrad Tavallai
SJSophonie J Jean
Sophonie J Jean
Paul DentPaul Dent
Paul Dent
The chaperone GRP78/Dna K is conserved throughout evolution down to prokaryotes. The GRP78 inhibitor OSU-03012 (AR-12) interacted with sildenafil (Viagra) or tadalafil (Cialis) to rapidly reduce GRP78 levels in eukaryotes and as a single agent reduce Dna K levels in prokaryotes. Similar data with the drug combination were obtained for: HSP70, HSP90, GRP94, GRP58, HSP27, HSP40 and HSP60. OSU-03012/sildenafil treatment killed brain cancer stem cells and decreased the expression of: NPC1 and TIM1; LAMP1; and NTCP1, receptors for Ebola/Marburg/Hepatitis A, Lassa fever, and Hepatitis B viruses, respectively. Pre-treatment with OSU-03012/sildenafil reduced expression of the coxsakie and adenovirus receptor in parallel with it also reducing the ability of a serotype 5 adenovirus or coxsakie virus B4 to infect and to reproduce. Similar data were obtained using Chikungunya, Mumps, Measles, Rubella, RSV, CMV, and Influenza viruses. OSU-03012 as a single agent at clinically relevant concentrations killed laboratory generated antibiotic resistant E. coli and clinical isolate multi-drug resistant N. gonorrhoeae and MRSE which was in bacteria associated with reduced Dna K and Rec A expression. The PDE5 inhibitors sildenafil or tadalafil enhanced OSU-03012 killing in N. gonorrhoeae and MRSE and low marginally toxic doses of OSU-03012 could restore bacterial sensitivity in N. gonorrhoeae to multiple antibiotics. Thus, Dna K and bacterial phosphodiesterases are novel antibiotic targets, and inhibition of GRP78 is of therapeutic utility for cancer and also for bacterial and viral infections. J. Cell. Physiol. 230: 1661–1676, 2015. © 2014 The Authors. Journal of Cellular Physiology Published by Wiley Periodicals, Inc.

31 January 2010 in Cancer Research
Verified
Journal Article
Open access
PDF file
AYAdly Yacoub
Adly Yacoub
HHHossein A. Hamed
Hossein A. Hamed
JAJeremy Allegood
Jeremy Allegood
CMClint Mitchell
Clint Mitchell
SSSarah Spiegel
Sarah Spiegel
Paul DentPaul Dent
Paul Dent
Melanoma differentiation associated gene-7(mda-7) encodes IL-24, a cytokine that can selectively trigger apoptosis in transformed cells. Recombinant mda-7 adenovirus (Ad.mda-7) effectively kills glioma cells, offering a novel gene therapy strategy to address deadly brain tumors. In this study, we defined the proximal mechanisms by which Ad-mda-7 kills glioma cells. Key factors implicated included activation of the endoplasmic reticulum stress kinase protein kinase R–like endoplasmic reticulum kinase (PERK), Ca++ elevation, ceramide generation and reactive oxygen species (ROS) production. PERK inhibition blocked ceramide or dihydroceramide generation, which were critical for Ca++ induction and subsequent ROS formation. Activation of autophagy and cell death relied upon ROS formation, the inhibition of which ablated Ad.mda-7–killing activity. In contrast, inhibiting TRX induced by Ad.MDA-7 enhanced tumor cytotoxicity and improved animal survival in an orthotopic tumor model. Our findings indicate that mda-7/IL-24 induces an endoplasmic reticulum stress response that triggers production of ceramide, Ca2+, and ROS, which in turn promote glioma cell autophagy and cell death. Cancer Res; 70(3); 1120–9